FavStocks Stock Market Forum - Hot Stocks http://forums.favstocks.com/ Hot stocks on AMEX, NASDAQ, NYSE, OTC BB, and other OTC en Mon, 13 Sep 2010 17:05:21 GMT vBulletin 60 http://forums.favstocks.com/images/vblue_dark/misc/rss.png FavStocks Stock Market Forum - Hot Stocks http://forums.favstocks.com/ ALXA - Alexza Pharmaceuticals http://forums.favstocks.com/hot-stocks/2112-alxa-alexza-pharmaceuticals.html Mon, 13 Sep 2010 15:54:09 GMT ALXA is starting its run into Oct FDA date... Going up slowly every day in a channel.. Should break out soon as we get closer to 10/11, less than a... ALXA is starting its run into Oct FDA date... Going up slowly every day in a channel.. Should break out soon as we get closer to 10/11, less than a month away. Very bullish. ]]> Hot Stocks sterling http://forums.favstocks.com/hot-stocks/2112-alxa-alexza-pharmaceuticals.html 2010 Third Quarter Plays http://forums.favstocks.com/hot-stocks/2045-2010-third-quarter-plays.html Mon, 13 Sep 2010 11:42:41 GMT Short interest as of 31 Aug is out Largest Nasdaq Short Interest Positions as of Aug. 31 - Bloomberg... Short interest as of 31 Aug is out

Largest Nasdaq Short Interest Positions as of Aug. 31 - Bloomberg

and ARNA seems to be in the top 20 with a little over 5mm shares short, over 6.77 days to cover. Makes sense with the big binary events coming up.

Another one of interest, SOMX, over 25% of the available shares are short (8mm/36mm). Over 1.7 days to cover. Doesn't make sense, nothing but a bright future for this company. already priced at pre-FDA approval prices. more proof that something good will come this way ]]>
Hot Stocks gaab http://forums.favstocks.com/hot-stocks/2045-2010-third-quarter-plays.html
WMT Levels To Follow http://forums.favstocks.com/hot-stocks/2111-wmt-levels-follow.html Wed, 08 Sep 2010 14:34:52 GMT WMT is a leading retail stock that will often set the tone for the sector. Today WMT is trading lower by 0.17 cents to $51.69. The stock will have... WMT is a leading retail stock that will often set the tone for the sector. Today WMT is trading lower by 0.17 cents to $51.69. The stock will have short term minor intra-day support around the $51.60 level. The next intra-day support area for the stock should it decline further will be around the $51.40 area. Both support areas could see small intra-day bounces.

]]>
Hot Stocks inthemoneystocks http://forums.favstocks.com/hot-stocks/2111-wmt-levels-follow.html
Phase III Data in July = Next Dendreon !!! http://forums.favstocks.com/hot-stocks/2032-phase-iii-data-july-next-dendreon.html Wed, 08 Sep 2010 12:25:19 GMT BNC HITS NEW 52W HIGH ..Bioniche is still very very cheap ...GLTA 100% BUY Signal is Created Barchart.com Stocks | BNC.TO Detailed Opinion |... BNC HITS NEW 52W HIGH ..Bioniche is still very very cheap ...GLTA


100% BUY Signal is Created
Barchart.com Stocks | BNC.TO Detailed Opinion | Bioniche Life Scie Com Npv Detailed Opinion


Good News Coming ...

PharmaTelevision Sept.22 20110
PharmaTelevision - PTV Guide

Bioniche: Graeme McRae on Bioniche's Newly Discovered Cancer Killing Bacteria
In this episode of PharmaTelevision News Review, Fintan Walton talks with Graeme McRae, CEO at Bioniche. Filmed at BioChicago 2010 in , USA, they discuss:

• Origins and focus of Bioniche

• Mechanism of action behind Bioniche's bladder cancer product

• Scope of the product

• Animal health products

• Drugs in food safety

• Reduction of chances of E-coli breakout

Should be interesting ]]>
Hot Stocks BiotechMaster http://forums.favstocks.com/hot-stocks/2032-phase-iii-data-july-next-dendreon.html
GLD Is Strong Again, However, Major Resistance In Play. http://forums.favstocks.com/hot-stocks/2110-gld-strong-again-however-major-resistance-play.html Tue, 07 Sep 2010 14:07:32 GMT The GLD is strong again this morning trading higher by 0.90 cents to $122.77. The all-time high for the GLD was $123.58 made in late June 2010.... The GLD is strong again this morning trading higher by 0.90 cents to $122.77. The all-time high for the GLD was $123.58 made in late June 2010. Therefore, until the GLD breaks and closes above that level on the daily chart this area is still going to be important resistance for the ETF.

]]>
Hot Stocks inthemoneystocks http://forums.favstocks.com/hot-stocks/2110-gld-strong-again-however-major-resistance-play.html
Investment http://forums.favstocks.com/hot-stocks/2109-investment.html Tue, 07 Sep 2010 12:45:10 GMT Hi, If you are wondering to earn money online. Now these days most of the people do online business. It provides us facility to do work any time... Hi,
If you are wondering to earn money online. Now these days most of the people do online business. It provides us facility to do work any time and from anywhere. If you have some money to invest then stock market would be good for you, it’s very effective way to make money rapidly. You could just read some ebook for stock market and gain everything about online trading. Hope this will help you.

All the best!
____________________
nifty tips commodity tips ]]>
Hot Stocks brennan http://forums.favstocks.com/hot-stocks/2109-investment.html
PSDV - pSivida Corp. http://forums.favstocks.com/hot-stocks/951-psdv-psivida-corp.html Mon, 06 Sep 2010 02:15:27 GMT Alot has happened since the last post: * Alimera went public @ $11.00 a share * Alimera filed with the FDA for Priority Review and they... Alot has happened since the last post:

* Alimera went public @ $11.00 a share

* Alimera filed with the FDA for Priority Review and they granted it

* Citi came out with a recommendation for Alimera (ALIM) with a target
price of $15.00

* Alimera and PSDV should be in front of the FDA for a YES/NO decision sometime in Dec 2010

* The drug Lucentis (approved for AMD) and used off-label for DME (with success) sells for
$2000 a MONTH which means that a 3 year supply DOES cost $72,000

* Per the Alimera roadtrip Alimera's mgt said that they estimated the cost of Iluvien
to be around $5,000.

* So for a 3 year timeframe its (a) pay $72,000 or (b) pay $5000 AND avoid all those
MONTHLY needles in the eye.

* The P3 trial (using the INTENT TO TREAT METHOD) was a success.

* The P3 trial using the Modified Arts method was a success in 3 out of 4 cases.
(The 4th case's problem was that some people who were supposed to receive
Iluvien did not show up to take it)

* Citi thinks ALIM will get 9% market share after 24 months. (Their NUTS)

* Iluvien will capture 25% market share after 24 months.

-- Cost
-- Convenience
-- Equivalent or better efficacy

And results kick in starting in the 3rd week.

* PSDV will get $25 million on FDA approval

* PSDV will get 20% of profits - forever.

* Alimera has already filed in Europe will soon file in Canada. I forget when
they file in Asia.


























Quote:

Originally Posted by JohnM3 View Post
PSDV - pSivida

(a) Indication: DME
(b) USA Market Size
per President: $1 Billion to $3 Billion
(c) Phase 3 results: Dec-09 release date
(d) Product:IIuvien

a combination of a nano-tech thingie containing
the FDA approved drug fluocinolone acetonide (FA)

August 2009 Presentation
Error Report

They just released similar presentation at R&R in 9/9/09
Wall Street Webcasting - pSivida Corp.

(e) PSDV existing FDA approved products thus far

Vitraset - partner B&L
Retisert - req operation - partner B&L

IOW - nano thingies already in humans and nobody has
turned into ET ... yet ....

(f) The IIuvien product is partnered with Alimera Sciences - a
private company

Alimera Mgt
Management Team | Alimera Sciences

(g) As I see it - upcoming investor milestones

* Release trial data Dec-09
* If OK - submit NDA Apl-10
* Request "Expedited Review"

This would reduce approval YES/NO timeframe to
Sept/Oct - 2010

WARNING:
THIS IS A CRAP SHOOT.
IF THE TRIAL FAILS PSDV (imo) is OUT OF BUSINESS
cash wise ....

If the Trial succeeds I hope they try a 2.0 million++
share offering .... ++ potential for cash from
those warrants - but I don't know the terms

FDA approval is a whole different matter but lasers
approved for DME *suck* and there are no other
approved therapies. Drug *stuff* is about 2 years
behind.

Notes:

Very low daily share volume
Bid/Asked spreads as much as 25 cents
18 million shares outstanding
13 million warrants ($7) outstanding

(h) In the wings -

- PSDV is too cash poor $8 million to carry out
full blown Phase 3 Pancreatic trials - but thats
where they are going

- Phase 2a - 17 people - avg life time 309 days vs
expected 178 days - safety trial - Pancreatic Cancer

pSivida's BrachySil in Pancreatic Cancer Study Results to be Presented at the ASCO Gastrointestinal Cancers Symposium - Drugs.com MedNews

- Phase 2b - 6 people - london - dosing ranging trial
on people expected to die within 6 months from - Pancreatic Cancer

One patient who started Jun-08 was on BBC Mar-09

Brachysil | A-2-Z About Cancer

Their enrollment has completed
pSivida Corp: Enrollment complete in BrachySil Dose Ranging Study | Reuters

- Pancreatic Cancer product called P32 Biosilicon - or
Brachysil

The statistics below were given by the
President of pSivida (PSDV) on 9/10/2009
at the R&R conference.
.
.
Notes from the presentation:
.
.
Back Eye Market Size
---------------------------
AMD Dry - 1,700,000AMD Wet -
300,000
---------------------------
AMD Total 2,000,000
====================
.
.
Glaucoma - 4,000,000
.
.
Diabetic Retinopathy
--------------------------------
DME ..................... 1,000,000
Diabetic Proliferate - 3,000,000
--------------------------------
Diabetic Retinopathy 4,000,000
==========================
.
.
---------------------------------------
Total Back Eye Market Size - 10,000,000
===============================
.
.
Lucentis is realizing revenues of $800,000,000
for its AMD Wet application.
.
.
If IIuvien clears the FDA the market opportunity
is between $1 billion to $3 billion per the
President of Psivida.
.
.
Source:
Wall Street Webcasting - pSivida Corp.
.
.

Here is a post by pharout912 on yahoo that provides a brief history of the company
and where they are today .....

------------------------------------------
For those new to this stock a little history PSDV was a AU based company that was poorly managed and while getting licenses for technology they had no clue about what to do with it. They did a number of very poor financings and these hung over the stock until 2007.

The one thing they did right was buy ( merge ) with Control Delivery Systems which gave them access to all of the current eyecare technologys. Over a period of several years CDS's management (Ashton et al)took over PSDV. They got rid of technology and / or licensed it out to stop the finaical bleed. During this time they came under great financial duress as an old financing allowed a group to actively short the stock... to make a long story short PSDV current management did 5 things right.

1)Focus on core technology and trials by selling off the non-core deals ( neutraceticals anyone?)
2) Cut Costs (staff associated with non-core)
3) Decrease cash burn by reworking license deal and insure they could get to 2011
4) Write-downs of IP (non-recurring) to get things in line as they got rid of some of the chaff. This will help in the future as they have bitten the bullet.
5) Make it a US based business

These things took time and money and slowly PSDV got on track only to be hammered during the market pull back of last year.

In my view this is a valuation deal. What are the royalties of the drug going to be worth? Remember, they have to do little to make money as there is no real performance required. So lets ask a simple question, what if their royalty income is 15M ( very very conservative IMO). For me I think that means about 225M in value on the very low end and this could easily go to the 350-400M range with strong sales.... now don't forget the one time payments of 25M on approval (I expect it early 3rd quarter of next year - for the people who say a year after NDA please look at other recent timeframes)and 15M when their partner raises capital or 2001 whichever is first so now you have 40M cash hord and a real going concerm which is ripe for the picking..

As far as PPS I think value is the whole deal... do your own analysis and then divide by 18M and you have it... and that assumes their is no value placed on 40M in cash. Also, it does not place a value on the technology... which put in the right hands could be huge.

Here is my time line

- Early October confirmation of completion of the trial
- Early December - Release of Data.... this will be big deal if it is anything close to the PK study, which I fully expect
- February 2010 - Filing of NDA w/ expidited approval
- July 2010 - FDA Approval

I know it seems like a long time but don't forget as this continues to move along this path I have included no other deals / announcements and once that initial data is released they will show up on everyones radar....maybe a deal or two? Don't forget big boys like doing deals with companies that have just reported great results.

Ohh just a note.. the insiders have sold nothing. They are in for the ride and to me that says it all.

Hope that helps.. happy hunting.

PS. Froma technical standpoint $4-5 is going to be a hard slog. Once this clears I expect that there will be much stronger upward momentum. This is not a day traders stock IMO because with the key blocks not selling the MM's will run it up and down and take money from those who can't afford to hold and gamble a little.

Yahoo! Message Boards - pSivida Corp. - RE: A Little History

]]>
Hot Stocks JohnM3 http://forums.favstocks.com/hot-stocks/951-psdv-psivida-corp.html
IVD (Mcap 15 M$) Approval within 5 Weeks http://forums.favstocks.com/hot-stocks/2105-ivd-mcap-15-m-approval-within-5-weeks.html Thu, 02 Sep 2010 16:05:11 GMT Last chance to buy under 1$.... Last chance to buy under 1$.... ]]> Hot Stocks BiotechMaster http://forums.favstocks.com/hot-stocks/2105-ivd-mcap-15-m-approval-within-5-weeks.html IGSM - IGSM Group Inc. (Pink) Low float; Early bird Alert ~ http://forums.favstocks.com/hot-stocks/2102-igsm-igsm-group-inc-pink-low-float-early-bird-alert.html Thu, 02 Sep 2010 15:29:52 GMT "Company has been in a quiet period while working with Salberg & Company to prepare audited financials, which is necessary for them to up list from the pinks. The 10k is finally in final stages of being completed (if not completed already). " I looked on the net trieng to find something on this and could not find anything not even on igsm's website. Could u point me in the right direction? ]]> Hot Stocks AWPS http://forums.favstocks.com/hot-stocks/2102-igsm-igsm-group-inc-pink-low-float-early-bird-alert.html Lbsr http://forums.favstocks.com/hot-stocks/2095-lbsr.html Thu, 02 Sep 2010 09:26:27 GMT Got in 2 weeks ago, this is the latest news and correct me if I'm wrong but this can't be good?

"Form 8-K for LIBERTY STAR URANIUM & METALS CORP.


--------------------------------------------------------------------------------

1-Sep-2010

Regulation FD Disclosure



Item 7.01 Regulation FD Disclosure
On August 26, 2010, Platinum Long Term Growth VI LLC and Alpha Capital Anstalt, two former lenders of the Company (the "Plaintiffs"), filed lawsuit in the United States District Court, Southern District of New York, against Liberty Star and James Briscoe, our president and CEO. The Plaintiffs are seeking to require Liberty Star to honor outstanding warrants held by the Plaintiffs at an exercise price of $0.002 (two tenths of one cent) per share and to issue to the Plaintiffs ten times the number of warrants that Liberty Star has on record, or in the alternative money damages. The claim is based on a provision in the warrant agreements that would permit a "ratchet down" of price and a multiplication of number of warrants in the event of certain share issuances by Liberty Star.

The Plaintiffs are claiming that Platinum is entitled to 201,053,015 warrants and that Alpha is entitled to 240,919,010 warrants all exercisable at $0.002 per share. If the Plaintiffs are successful in their lawsuit, a total of 589,177,000 warrants would be outstanding at an exercise price of $0.002 to all warrant holders who are former lenders to our company. These warrants all contain a cashless exercise feature, permitting issuance of shares without payment of any cash to the company. The Plaintiffs are also claiming money damages for non-compliance with what they claim are the terms of the warrants, costs and attorney fees incurred in the action.

Currently, there are 434,784,657 common shares of Liberty Star outstanding. If the warrant holders are successful in their lawsuit, they and other warrant holders could exercise warrants for over 55% of the company's equity at a price of $0.002 per share. However, there are contractual limits on the percentage of the company's outstanding common shares which any warrant holder can hold at the time of exercise (ie not more than 9.99% of the company's outstanding shares), so individually none of them could control the company through the exercise of warrants.

We are vigorously defending against the lawsuit and have through our attorney made an appearance in court. Our defense is, in part, that no "ratchet down" provision is in effect. If we are successful on that defence alone, that would leave all former lender warrant holders with 58,917,700 warrants exercisable at $0.02 (two cents) per share. ]]>
Hot Stocks maritska http://forums.favstocks.com/hot-stocks/2095-lbsr.html
NILE Therapeutics price target http://forums.favstocks.com/hot-stocks/2108-nile-therapeutics-price-target.html Wed, 01 Sep 2010 19:18:45 GMT August 16, 2010 Nile Therapeutics Reports 2010 Second Quarter Financial Results About Nile Therapeutics -- Nile Therapeutics, Inc.... August 16, 2010

Nile Therapeutics Reports 2010 Second Quarter Financial Results


About Nile Therapeutics

-- Nile Therapeutics, Inc. (NASDAQ: NLTX), a company focused on the development of novel therapeutics for heart failure patients today.......

..................


Update on CD-NP

During June 2010, Nile completed enrolling a placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure ("ADHF") in the United States, Germany and Israel. In total, 77 patients were randomized into four doses of CD-NP (1.25, 2.5, 3.75 and 5 ng/kg/min) vs. placebo. The last patient visit occurred at the end of July and final results from the study are expected in the fourth quarter of 2010. Also in the fourth quarter of 2010, Nile plans to submit to the FDA for review and discussion, the clinical protocol for a double-blind, placebo controlled Phase IIb study of CD-NP in ADHF patients.


Nile Therapeutics, Inc.
August 20, 2010
NLTX

Share Nile Therapeutics, Inc. (NLTX - Analyst Report) is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF).
Prior phase I and phase II data so far has been highly encouraging. With a market capitalization of only $14 million, Nile Therapeutics shares are bafflingly under-valued.

We believe with positive data from the ongoing phase II program in hand the company is worth at least $80 to 100 million. Taking the mid-range at $90 million, and then backing out the $20 million most likely required to fund the phase IIb program, we arrive at a value of $70 million for Nile Therapeutics. This equates to a price of $2.00 per share.


This study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure


Verified by Nile Therapeutics, March 2010
First Received: February 6, 2009 Last Updated: March 5, 2010 History of Changes
Sponsor: Nile Therapeutics
Information provided by: Nile Therapeutics
ClinicalTrials.gov Identifier: NCT00839007
Purpose
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.


Condition Intervention Phase
Acute Decompensated Heart Failure
Drug: CD-NP
Phase II

Official Title: A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Further study details as provided by Nile Therapeutics:

Primary Outcome Measures:
The occurence of hypotensive events, clinical symptoms, and renal function change with CD-NP infusion. [ Time Frame: Up to 72 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 75
Study Start Date: June 2009
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)


Make your considerations ...
Now the price is 0.62 ]]>
Hot Stocks giasone http://forums.favstocks.com/hot-stocks/2108-nile-therapeutics-price-target.html
<![CDATA[KBLB alerted by Richard Appel's ********** yesterday]]> http://forums.favstocks.com/hot-stocks/2106-kblb-alerted-richard-appels-yesterday.html Wed, 01 Sep 2010 08:20:16 GMT pre promotion stocks could be the reason for the 20% rise in share price. pre promotion stocks could be the reason for the 20% rise in share price. ]]> Hot Stocks rain44fun http://forums.favstocks.com/hot-stocks/2106-kblb-alerted-richard-appels-yesterday.html SPEX - Spherix Inc. - NASDAQ http://forums.favstocks.com/hot-stocks/1676-spex-spherix-inc-nasdaq.html Tue, 31 Aug 2010 08:21:38 GMT Ciao Pslice84 ! Excuse my English ! Yes thanks but I knew..... my entry price is low enough. I can afford to risk the wait .... Now, Everything... Ciao Pslice84 ! Excuse my English !

Yes thanks but I knew..... my entry price is low enough. I can afford to risk the wait ....
Now, Everything 's guessing when the option will be exercised...
Should they do so after the announcement of the results!?
What do you think about? ]]>
Hot Stocks giasone http://forums.favstocks.com/hot-stocks/1676-spex-spherix-inc-nasdaq.html
Can Google Predict the Future? http://forums.favstocks.com/hot-stocks/2084-can-google-predict-future.html Mon, 30 Aug 2010 20:44:39 GMT Indeed it is math - however, linear regression is a powerful tool that is used frequently in the investment comunity. Best, theweeklytrade.com Indeed it is math - however, linear regression is a powerful tool that is used frequently in the investment comunity.

Best,

theweeklytrade.com ]]>
Hot Stocks theweeklytrade http://forums.favstocks.com/hot-stocks/2084-can-google-predict-future.html
BSIO - (Shell stock) is down 72 %. Should make a bounce http://forums.favstocks.com/hot-stocks/2074-bsio-shell-stock-down-72-should-make-bounce.html Mon, 30 Aug 2010 07:18:20 GMT i dont think that its now bargain. i would wait a bit. i dont think that its now bargain. i would wait a bit. ]]> Hot Stocks Wasserblock http://forums.favstocks.com/hot-stocks/2074-bsio-shell-stock-down-72-should-make-bounce.html Weekend Technical Analysis - Market Prepares For Jobs Data As Profits For Members M http://forums.favstocks.com/hot-stocks/2104-weekend-technical-analysis-market-prepares-jobs-data-profits-members-m.html Sun, 29 Aug 2010 17:10:30 GMT http://www.youtube.com/watch?v=9zSEbjkxvqc InTheMoneyStocks.com breaks out the key technical analysis techniques they have become famous for. They...

InTheMoneyStocks.com breaks out the key technical analysis techniques they have become famous for. They analyze the charts on the market to showcase their technical trend line analysis, price, pattern and time values. By utilizing these methods and not using the common technical tools which almost never work anymore, they are able to call every major and minor market move avoiding Wall Street hype. InTheMoneyStocks.com looks at major support and resistance levels on the charts telling their viewers where the market will rise and fall. They talk about major rules that must be learned. Enjoy and come get their premium daily, month, weekly and intra day expert guidance on the markets, gold, oil, us$ and stocks in their premium nightly videos, daily market reports, pro trader watch list, hidden gems and technical tactics. ]]>
Hot Stocks inthemoneystocks http://forums.favstocks.com/hot-stocks/2104-weekend-technical-analysis-market-prepares-jobs-data-profits-members-m.html
Bilb http://forums.favstocks.com/hot-stocks/2101-bilb.html Fri, 27 Aug 2010 16:21:45 GMT Bill the Butcher Has Record Monthly Sales in July: Bill the Butcher Has Record Monthly Sales in July - MarketWatch... Bill the Butcher Has Record Monthly Sales in July: Bill the Butcher Has Record Monthly Sales in July - MarketWatch ]]> Hot Stocks Jimmy http://forums.favstocks.com/hot-stocks/2101-bilb.html Bill the Butcher Inc http://forums.favstocks.com/hot-stocks/2103-bill-butcher-inc.html Fri, 27 Aug 2010 15:06:43 GMT Thank's for the link!
Have you heard ,that the farms benefit because BILB offers a venue beyond the farmers market and exposure to new customers. The competition deals with large processors and ranchers and simply do not have the interest or time to cultivate these unique relationships.
BILB visits and verifies source farms and can offer the Bill the Butcher Natural standard on all of its products. None of BILB’s products have been raised on steroids, hormones, antibiotics or with genetically modified feed. ]]>
Hot Stocks Grigorchenko http://forums.favstocks.com/hot-stocks/2103-bill-butcher-inc.html
SOMX - Somaxon Pharmaceuticals, Inc. http://forums.favstocks.com/hot-stocks/310-somx-somaxon-pharmaceuticals-inc.html Wed, 25 Aug 2010 12:31:26 GMT Somaxon Pharmaceuticals Announces Silenor® Co-Promotion Agreement with Procter & Gamble!


Somaxon Pharmaceuticals Announces Silenor® Co-Promotion Agreement with Procter & Gamble ]]>
Hot Stocks kilimanjaro http://forums.favstocks.com/hot-stocks/310-somx-somaxon-pharmaceuticals-inc.html
RIGH - Right Smile http://forums.favstocks.com/hot-stocks/2099-righ-right-smile.html Mon, 23 Aug 2010 01:30:13 GMT radar it this week..ready to bounce...imo RIGH - SharpCharts Workbench - StockCharts.com... radar it this week..ready to bounce...imo

RIGH - SharpCharts Workbench - StockCharts.com

RIGH RightSmile, Inc.: Reporting Status, Officers, Directors for RightSmile, Inc. - OTCMarkets.com

Float 872,048,872 as of Aug 13, 2010 ]]>
Hot Stocks Jim Broski http://forums.favstocks.com/hot-stocks/2099-righ-right-smile.html